SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells

Background: TP53 gene mutations are common in breast cancer and are linked to chemoresistance. p63, a p53 family member, can induce apoptosis independently of p53, representing a potential therapeutic target in TP53-mutant tumors. This study evaluated the synergistic effects of SB...

Descrición completa

Detalles Bibliográficos

Principais autores:	Yu-Ling Kou, Yu-Jie Liu, Tzu-Chi Hsu, Kuan-Yo Wu, Sih-Tong Chen, Jing-Yan Chen, Kuan-Yu Lin, Hsiao-Hsuan Wang, Yi-Ting Cheng, Chia-Chi Chen, Bi-He Cai
Formato:	Artigo
Idioma:	Inglês
Publicado:	IMR Press 2025-12-01
Series:	Frontiers in Bioscience-Landmark
Assuntos:	sb431542 doxorubicin p63 tumor suppressor protein p53 mutation breast cancer drug interactions
Acceso en liña:	https://www.imrpress.com/journal/FBL/30/12/10.31083/FBL45389
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!